Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

True Leaf Medicine International ltd. Offers $110,000 Non-Brokered Private Placement

C.MJ

Vancouver, British Columbia--(Newsfile Corp. - August 7, 2015) - True Leaf Medicine International Ltd. has arranged a non-brokered private placement of up to 1,375,000 units at a subscription price of e$0.08 per unit to eligible subscribers for gross proceeds of up to $110,000.

Each unit will consist of one common share and one full share purchase warrant. Each whole warrant will be exercisable into one additional common share of the company at 15 cents per warrant share for a period of 24 months from the closing.

Finders' fees or commissions may be payable by the company in connection with this private placement.

The common shares issued or issuable pursuant to the private placement will be restricted from trading for a four-month hold period in accordance with applicable securities laws and, if required, the policies of the exchange. The proceeds of this private placement are for the company's general and administrative expenses.

About True Leaf

True Leaf Medicine International Ltd, is a Canadian medical marijuana company carving a niche in the fast growing and dynamic $60 billion pet industry. A subsidiary, True Leaf Pet, will focus on the natural pet product sector with a line consisting of innovative hemp based functional pet chews, followed by CBD supplements for pets in the USA market. This will lay a profitable foundation for the company's long term strategy to secure a new animal drug application for a cannabis-based pet medication sold via veterinary prescription in the $13.8 billion pet medication market.

Contact:
Paul Sullivan
Break Through Communications
O: 604-685-4742
M: 604-603-7358
p.sullivan@breakthroughpr.com

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today